Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Top Cited Papers
- 2 September 2019
- journal article
- letter
- Published by Springer Nature in Nature Medicine
- Vol. 25 (9) , 1408-1414
Abstract
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL)1,2,3,4,5, but toxicity, including cytokine-release syndrome (CRS) and neurotoxicity, limits broader application. Moreover, 40–60% of patients relapse owing to poor CAR T cell persistence or emergence of CD19− clones. Some factors, including the choice of single-chain spacer6 and extracellular7 and costimulatory domains8, have a profound effect on CAR T cell function and persistence. However, little is known about the impact of CAR binding affinity. There is evidence of a ceiling above which increased immunoreceptor affinity may adversely affect T cell responses9,10,11. We generated a novel CD19 CAR (CAT) with a lower affinity than FMC63, the high-affinity binder used in many clinical studies1,2,3,4. CAT CAR T cells showed increased proliferation and cytotoxicity in vitro and had enhanced proliferative and in vivo antitumor activity compared with FMC63 CAR T cells. In a clinical study (CARPALL, NCT02443831), 12/14 patients with relapsed/refractory pediatric B cell acute lymphoblastic leukemia treated with CAT CAR T cells achieved molecular remission. Persistence was demonstrated in 11 of 14 patients at last follow-up, with enhanced CAR T cell expansion compared with published data. Toxicity was low, with no severe CRS. One-year overall and event-free survival were 63% and 46%, respectively.Keywords
Funding Information
- CHILDREN with CANCER UK (522356)
- DH | National Institute for Health Research (514413)
- Great Ormond Street Hospital Charity (543539, 522356)
This publication has 33 references indexed in Scilit:
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T CellsClinical Cancer Research, 2013
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEffFly, 2012
- Simultaneous Generation of Multivirus-specific and Regulatory T Cells for Adoptive ImmunotherapyJournal of Immunotherapy, 2012
- Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell FunctionThe Journal of Immunology, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- The use of differential scanning fluorimetry to detect ligand interactions that promote protein stabilityNature Protocols, 2007
- CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor EnhancesIn vivoPersistence and Antitumor Efficacy of Adoptively Transferred T CellsCancer Research, 2006
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- Preparation and characterization of a chimeric CD 19 monoclonal antibodyImmunology & Cell Biology, 1991